

**UNITED STATES BANKRUPTCY COURT  
SOUTHERN DISTRICT OF NEW YORK**

In re:

PURDUE PHARMA L.P., *et al.*,

Debtors.<sup>1</sup>

Chapter 11

Case No. 19-23649 (RDD)

(Jointly Administered)

**FORTIETH MONTHLY FEE STATEMENT OF FTI CONSULTING, INC. FOR  
COMPENSATION FOR SERVICES RENDERED AND REIMBURSEMENT OF  
EXPENSES INCURRED AS FINANCIAL ADVISOR TO THE AD HOC COMMITTEE  
OF GOVERNMENTAL AND OTHER CONTINGENT LITIGATION CLAIMANTS FOR  
THE PERIOD FROM JANUARY 1, 2023 THROUGH JANUARY 31, 2023**

Name of Applicant:	FTI Consulting, Inc.
Authorized to provide Professional Services to:	Ad Hoc Committee of Governmental and Other Contingent Litigation Claimants
Date of Order Approving Debtors' Payment of Fees and Expenses of Applicant:	December 2, 2019 [ECF No. 553]
Period for which compensation and reimbursement is sought:	January 1, 2023 through January 31, 2023
Monthly Fees Incurred:	\$98,523.50

---

1. The Debtors in these chapter 11 cases, along with the last four digits of each Debtor's registration number in the applicable jurisdiction, are as follows: Purdue Pharma L.P. (7484), Purdue Pharma Inc. (7486), Purdue Transdermal Technologies L.P. (1868), Purdue Pharma Manufacturing L.P. (3821), Purdue Pharmaceuticals L.P. (0034), Imbrium Therapeutics L.P. (8810), Adlon Therapeutics L.P. (6745), Greenfield BioVentures L.P. (6150), Seven Seas Hill Corp. (4591), Ophir Green Corp. (4594), Purdue Pharma of Puerto Rico (3925), Avrio Health L.P. (4140), Purdue Pharmaceutical Products L.P. (3902), Purdue Neuroscience Company (4712), Nayatt Cove Lifesciences Inc. (7805), Button Land L.P. (7502), Rhodes Associates L.P. (N/A), Paul Land Inc. (7425), Quidnick Land L.P. (7584), Rhodes Pharmaceuticals L.P. (6166), Rhodes Technologies (7143), UDF LP (0495), SVC Pharma LP (5717), and SVC Pharma Inc. (4014). The Debtors' corporate headquarters is located at One Stamford Forum, 201 Tresser Boulevard, Stamford, CT 06901.

Monthly Expenses Incurred: \$0.00

Total Fees and Expenses Due: \$98,523.50

This is a: X monthly \_\_\_\_\_interim \_\_\_\_\_final application

**PRIOR APPLICATIONS:**

<b>Docket No./Filed</b>	<b>Compensation Period</b>	<b>Requested</b>		<b>Approved</b>	
		<b>Fees</b>	<b>Expenses</b>	<b>Fees</b>	<b>Expenses</b>
Docket No. 635 Filed On 12/9/2019	9/19/2019 – 10/31/2019	\$778,791.50	\$680.61	\$771,291.50	\$680.61
Docket No. 741 Filed On 1/13/2020	11/1/2019 – 11/30/2019	\$827,575.00	\$899.41	\$820,075.00	\$899.41
Docket No. 852 Filed on 2/20/2020	12/1/2019 – 12/31/2019	\$802,036.50	\$2,284.19	\$794,536.50	\$2,284.19
Docket No. 916 Filed on 3/12/2020	1/1/2020 – 1/31/2020	\$774,662.00	\$11,530.84	\$767,162.00	\$11,530.84
Docket No. 1090 Filed on 4/27/2020	2/1/2020 – 2/29/2020	\$615,089.00	\$6,141.22	\$610,714.00	\$6,141.22
Docket No. 1171 Filed on 5/19/2020	3/1/2020 – 3/31/2020	\$561,863.50	\$67.08	\$557,488.50	\$67.08
Docket No. 1251 Filed on 6/10/2020	4/1/2020 – 4/30/2020	\$428,303.00	\$1,732.28	\$423,928.00	\$1,732.28
Docket No. 1379 Filed on 7/13/2020	5/1/2020 – 5/31/2020	\$303,367.00	\$4,325.26	\$298,992.00	\$4,325.26
Docket No. 1651 Filed on 9/2/2020	6/1/2020 – 6/30/2020	\$374,753.00	\$96.90	\$372,253.00	\$ 96.90
Docket No. 1725 Filed on 9/25/2020	7/1/2020 – 7/31/2020	\$446,975.50	\$0.00	\$444,475.50	\$0.00
Docket No. 1850 Filed on 10/26/2020	8/1/2020 – 8/31/2020	\$261,092.00	\$108.25	\$258,592.00	\$108.25
Docket No. 1950 Filed on 10/26/2020	9/1/2020 – 9/30/2020	\$357,546.50	\$0.00	\$355,046.50	\$0.00
Docket No. 2031 Filed on 11/24/2020	9/19/2019 – 9/30/2020	\$44,462.00	\$0.00	\$41,462.60	\$0.00
Docket No. 2154 Filed on 12/18/2020	10/1/2020 – 10/31/2020	\$356,078.50	\$0.00	\$353,078.50	\$0.00
Docket No. 2308 Filed on 1/20/2021	11/1/2020 – 11/30/2020	\$450,827.00	\$0.00	\$447,827.00	\$0.00
Docket No. 2503 Filed on 3/17/2021	12/1/2020 – 12/31/2020	\$308,146.00	\$0.00	\$305,146.00	\$0.00
Docket No. 2504 Filed on 3/17/2021	1/1/2021 – 1/31/2021	\$493,773.50	\$0.00	\$490,773.50	\$0.00
Docket No. 2848 Filed on 5/12/2021	2/1/2021 – 2/28/2021	\$381,199.00	\$9.99	\$377,458.99	\$9.99
Docket No. 2849 Filed on 5/12/2021	3/1/2021 – 3/31/2021	\$513,645.00	\$0.00	\$509,895.00	\$0.00
Docket No. 3017 Filed on 6/11/2021	4/1/2021 – 4/30/2021	\$415,904.00	\$0.00	\$412,154.00	\$0.00
Docket No. 3225 Filed on 7/15/2021	5/1/2021 – 5/31/2021	\$363,711.00	\$40.00	\$360,001.00	\$40.00
Docket No. 3747 Filed on 9/9/2021	6/1/2021 – 6/30/2021	\$303,427.50	\$0.00	\$299,677.50	\$0.00

**PRIOR APPLICATIONS (cont.):**

Docket No./Filed	Compensation Period	Requested		Approved	
		Fees	Expenses	Fees	Expenses
Docket No. 3798 Filed on 9/21/2021	7/1/2021 – 7/31/2021	\$431,630.50	\$135.81	\$427,880.50	\$135.81
Docket No. 3941 Filed on 10/14/2021	8/1/2021 – 8/31/2021	\$284,159.00	\$20.94	\$280,409.00	\$20.94
Docket No. 4097 Filed on 11/11/2021	9/1/2021 – 9/30/2021	\$244,958.50	\$0.00	\$241,208.50	\$0.00
Docket No. 4225 Filed on 12/15/2021	10/1/2021 – 10/31/2021	\$368,998.50	\$40.00	\$367,498.50	\$40.00
Docket No. 4311 Filed on 1/26/2022	11/1/2021 – 11/30/2021	\$255,094.50	\$1,160.04	\$253,594.50	\$1,160.04
Docket No. 4312 Filed on 1/26/2022	12/1/2021 – 12/31/2021	\$192,786.50	\$0.00	\$191,286.50	\$0.00
Docket No. 4395 Filed on 2/25/2022	1/1/2022 – 1/31/2022	\$314,564.00	\$0.00	\$313,064.00	\$0.00
Docket No. 4654 Filed on 4/12/2022	2/1/2022 – 2/28/2022	\$181,198.50	\$8.00	\$178,888.84	\$8.00
Docket No. 4826 Filed on 5/16/2022	3/1/2022 – 3/31/2022	\$267,504.00	\$44.03	\$265,194.33	\$44.03
Docket No. 4833 Filed on 5/16/2022	4/1/2022 – 4/30/2022	\$175,704.00	\$0.00	\$173,394.33	\$0.00
Docket No. 4950 Filed on 7/12/2022	5/1/2022 – 5/31/2022	\$98,099.50	\$0.00	\$96,849.50	\$0.00
Docket No. 5005 Filed on 8/8/2022	6/1/2022 – 6/30/2022	\$53,624.00	\$0.00	\$52,374.00	\$0.00
Docket No. 5051 Filed on 8/31/2022	7/1/2022 – 7/31/2022	\$53,023.00	\$0.00	\$51,773.00	\$0.00
Docket No. 5132 Filed on 10/12/2022	8/1/2022 – 8/31/2022	\$35,470.00	\$0.00	\$34,220.00	\$0.00
Docket No. 5240 Filed on 11/15/2022	9/1/2022 – 9/30/2022	\$53,219.00	\$8.00	\$52,344.00	\$8.00
Docket No. 5341 Filed on 1/13/2023	10/1/2022 – 10/31/2022	\$30,107.50	\$0.00	\$29,232.50	\$0.00
Docket No. 5342 Filed on 1/13/23	11/1/2022 – 11/30/2022	\$31,105.00	\$0.00	\$30,230.00	\$0.00
Docket No. 5393 Filed on 2/1/23	12/1/2022 – 12/31/2022	\$42,190.00	\$0.00	\$41,315.00	\$0.00

Note: The fee examiner's agreed upon reductions of \$30,000, \$17,500, \$10,000, \$15,000, \$15,000, \$15,000, \$6,000, \$6,929, \$5,000, and \$3,500 were allocated evenly across fees from the first, second, third, fourth, fifth, sixth, seventh, eighth, ninth, and tenth interim period, respectively.

This statement (the “**Fee Statement**”) of FTI Consulting, Inc. (together with its wholly owned subsidiaries and independent contractors, “**FTI**”) as financial advisor to the Ad Hoc Committee of Governmental and Other Contingent Litigation Claimants of Purdue Pharma L.P., *et al.* (the “**Committee**”) is submitted in accordance with the *Order Establishing Procedures for Interim Compensation and Reimbursement of Expenses for Retained Professionals* [ECF No. 529] and the *Order Authorizing the Debtors to Assume the Reimbursement Agreement and Pay the Fees and Expenses of the Ad Hoc Committee’s Professionals* [ECF No. 553] entered on November 21, 2019 and December 2, 2019, respectively, (the “**Orders**”). In support of this Fee Statement, FTI respectfully states as follows.

1. The fees and expenses for the period from January 1, 2023 through and including January 31, 2023 (the “**Fee Period**”) amount to:

Professional Fees	\$98,523.50
Expenses	<u>0.00</u>
<b>TOTAL</b>	<b><u>\$98,523.50</u></b>

2. If no timely and proper objection is made by a party-in-interest within fourteen (14) days after service of this Fee Statement, the Debtors are authorized to pay 80% of professional fees and 100% of out-of-pocket expenses. These amounts are presented below.

Professional Fees at 80%	\$78,818.80
Expenses at 100%	<u>0.00</u>
<b>TOTAL</b>	<b><u>\$78,818.80</u></b>

3. The professionals providing services, hourly billing rates, the aggregate hours worked by each professional, and the aggregate hourly fees for each professional during the Fee Period are set forth on the schedule annexed hereto as **Exhibit “A”**.
4. A summary of aggregate hours worked and aggregate hourly fees for each task code during the Fee Period is set forth on the schedule annexed hereto as **Exhibit “B”**.

5. Detailed time entry by task code during the Fee Period is set forth on the schedule annexed hereto as **Exhibit “C”**.
6. FTI reserves the right to request, in subsequent fee statements and applications, reimbursement of any additional expenses incurred during the Fee Period, as such expenses may not have been captured to date in FTI’s billing system.

#### **NOTICE AND OBJECTION PROCEDURES**

7. Objections to this Fee Statement, if any, must be filed with the Court and served upon the Notice Parties so as to be received no later than April 13, 2023 (the “**Objection Deadline**”), setting forth the nature of the objection and the amount of fees or expenses at issue (an “**Objection**”).
8. If no objections to this Fee Statement are filed and served as set forth above, the Debtors shall promptly pay eighty percent (80%) of the fees and one hundred percent (100%) of the expenses identified herein.
9. If an objection to this Fee Statement is received on or before the Objection Deadline, the Debtors shall withhold payment of that portion of this Fee Statement to which the objection is directed and promptly pay the remainder of the fees and disbursements in the percentages set forth above. To the extent such an objection is not resolved, it shall be preserved and scheduled for consideration at the next interim fee application hearing to be heard by the Court.

Dated: New York, New York  
March 30, 2023

FTI CONSULTING, INC.  
Financial Advisors to the Ad Hoc Committee of  
Governmental and Other Contingent Litigation  
Claimants of Purdue Pharma L.P.

By: /s/ Matthew Diaz  
Matthew Diaz, Senior Managing Director  
1166 Avenue of the Americas, 15<sup>th</sup> Floor  
New York, New York 10036  
Telephone: (212) 499-3611  
Email: matt.diaz@fticonsulting.com

**EXHIBIT A****PURDUE PHARMA L.P., ET AL. - CASE NO. 19-23649****SUMMARY OF HOURS BY PROFESSIONAL****FOR THE PERIOD JANUARY 1, 2023 TO JANUARY 31, 2023**

<b>Professional</b>	<b>Position</b>	<b>Specialty</b>	<b>Billing Rate</b>	<b>Total Hours</b>	<b>Total Fees</b>
Diaz, Matthew	Sr Managing Director	Restructuring	\$ 1,325	31.0	\$ 41,075.00
Simms, Steven	Sr Managing Director	Restructuring	1,495	0.3	448.50
Shafer, Patterson	Managing Director	Healthcare	675	1.0	675.00
Bromberg, Brian	Sr Director	Restructuring	975	41.0	39,975.00
Kurtz, Emma	Sr Consultant	Restructuring	750	21.8	16,350.00
<b>GRAND TOTAL</b>				<b>95.1</b>	<b>\$ 98,523.50</b>

**EXHIBIT B**

**PURDUE PHARMA L.P., ET AL. - CASE NO. 19-23649**  
**SUMMARY OF HOURS BY TASK**  
**FOR THE PERIOD JANUARY 1, 2023 TO JANUARY 31, 2023**

<b>Task Code</b>	<b>Task Description</b>	<b>Total Hours</b>	<b>Total Fees</b>
1	Current Operating Results & Events	7.8	\$ 7,740.00
2	Cash & Liquidity Analysis	1.2	1,590.00
7	Analysis of Domestic Business Plan	37.6	38,046.00
9	Analysis of Employee Comp Programs	3.0	3,485.00
16	Analysis, Negotiate and Form of POR & DS	17.5	18,797.50
18	Review of Historical Transactions	19.0	19,340.00
20	General Mtgs with Debtor & Debtors' Prof	2.7	3,347.50
21	General Mtgs with Counsel and/or Ad Hoc Committee	3.3	3,447.50
24	Preparation of Fee Application	2.4	2,145.00
28	Review of IAC Business Plan	0.6	585.00
<b>GRAND TOTAL</b>		<b>95.1</b>	<b>\$ 98,523.50</b>

## EXHIBIT C

PURDUE PHARMA L.P., ET AL. - CASE NO. 19-23649

## DETAIL OF TIME ENTRIES

FOR THE PERIOD JANUARY 1, 2023 TO JANUARY 31, 2023

Task Category	Date	Professional	Hours	Activity
1	1/3/2023	Kurtz, Emma	0.6	Prepare daily summary of dataroom updates, key docket filings and media coverage for distribution to the team.
1	1/4/2023	Bromberg, Brian	0.5	Review Debtors' October operating results
1	1/4/2023	Diaz, Matthew	0.9	Review Debtors' October operating report.
1	1/6/2023	Bromberg, Brian	0.4	Review operating update report re: October results to provide comments.
1	1/6/2023	Kurtz, Emma	2.2	Prepare draft October monthly operating report presentation.
1	1/9/2023	Bromberg, Brian	0.6	Review October YTD update report slides to provide comments.
1	1/9/2023	Diaz, Matthew	0.9	Review draft report to the Committee re: October operating results.
1	1/9/2023	Kurtz, Emma	0.4	Prepare revisions to October operating report slides per comments from team.
1	1/9/2023	Kurtz, Emma	0.4	Prepare daily summary of dataroom updates, key docket filings and media coverage for distribution to the team.
1	1/11/2023	Diaz, Matthew	0.9	Review updated report to the committee re: October results to provide comments.
<b>1 Total</b>			<b>7.8</b>	
2	1/4/2023	Diaz, Matthew	0.5	Review Debtors' latest cash flow reporting.
2	1/10/2023	Diaz, Matthew	0.7	Review latest budget to actual cash reporting.
<b>2 Total</b>			<b>1.2</b>	
7	1/10/2023	Diaz, Matthew	0.4	Review of certain strategic alternatives.
7	1/17/2023	Diaz, Matthew	0.9	Review operations report.
7	1/18/2023	Bromberg, Brian	0.7	Review prior presentations on health initiatives.
7	1/18/2023	Bromberg, Brian	0.7	Review prior presentations on Avrio.
7	1/19/2023	Bromberg, Brian	0.5	Provide guidance to team re: presentation on business update.
7	1/19/2023	Bromberg, Brian	1.4	Review updated draft presentation for AHC re: business update.
7	1/19/2023	Kurtz, Emma	2.8	Prepare updated analysis and slides for Purdue update presentation re: operating results, Avrio, PHI, and Sackler net assets.
7	1/20/2023	Diaz, Matthew	2.1	Review initial draft presentation to the AHC re: business operations update to provide comments.
7	1/23/2023	Bromberg, Brian	0.6	Review draft business update presentation to provide comments.
7	1/23/2023	Bromberg, Brian	1.2	Review updated presentation on business update to provide comments.
7	1/23/2023	Bromberg, Brian	2.2	Review latest business plan from the Debtors to evaluate changes.
7	1/23/2023	Diaz, Matthew	0.9	Review revised business update presentation to the Committee to provide comments.
7	1/23/2023	Kurtz, Emma	1.1	Prepare revisions to draft update slides per internal comments.
7	1/23/2023	Kurtz, Emma	2.1	Prepare additional slides to incorporate into update presentation re: patent litigation.
7	1/24/2023	Bromberg, Brian	1.4	Prepare further revisions to business update presentation for the AHC.
7	1/24/2023	Bromberg, Brian	1.5	Participate in business plan call with Debtors.
7	1/24/2023	Bromberg, Brian	1.7	Review latest and prior business plan to evaluate changes to forecast and assumptions.
7	1/24/2023	Diaz, Matthew	1.3	Participate in the Debtors' business plan update.
7	1/24/2023	Diaz, Matthew	1.1	Review latest Purdue business plan to prepare for call.
7	1/24/2023	Diaz, Matthew	1.2	Review latest draft of update presentation to the Committee.
7	1/24/2023	Kurtz, Emma	0.6	Prepare additional revisions to Purdue update deck per latest news from Debtors.
7	1/24/2023	Kurtz, Emma	1.5	Attend call with Debtors and their advisors to discuss updated business plan.
7	1/25/2023	Bromberg, Brian	0.7	Finalize business update slides for AHC.
7	1/25/2023	Bromberg, Brian	1.1	Review materials to prepare for discussion with AHC on business plan.
7	1/25/2023	Bromberg, Brian	0.7	Review prior business plan cash flows.
7	1/25/2023	Bromberg, Brian	0.6	Review Debtors' YTD performance against business plan.
7	1/25/2023	Kurtz, Emma	0.4	Finalize presentation for AHC update call re: business update.
7	1/25/2023	Simms, Steven	0.3	Review update from team re: latest business plan projections.
7	1/26/2023	Bromberg, Brian	0.7	Review prior business plan cash flows.
7	1/26/2023	Bromberg, Brian	0.9	Review prior business plan adjustments.
7	1/27/2023	Bromberg, Brian	0.6	Discuss Avrio with Debtors advisors.
7	1/27/2023	Kurtz, Emma	0.5	Attend call with Debtors advisors re: Avrio.
7	1/28/2023	Bromberg, Brian	0.4	Discuss cash flow with Houlihan.
7	1/28/2023	Bromberg, Brian	0.7	Review cash flow model.
7	1/30/2023	Bromberg, Brian	0.7	Review business plan presentation.
7	1/30/2023	Diaz, Matthew	1.4	Review Debtors' updated business plan.
<b>7 Total</b>			<b>37.6</b>	
9	1/11/2023	Bromberg, Brian	0.5	Review Avrio retention payments.
9	1/11/2023	Diaz, Matthew	0.6	Review proposed retention payments.
9	1/23/2023	Bromberg, Brian	0.4	Review proposed retention payments re: Avrio.

## EXHIBIT C

PURDUE PHARMA L.P., ET AL. - CASE NO. 19-23649

## DETAIL OF TIME ENTRIES

FOR THE PERIOD JANUARY 1, 2023 TO JANUARY 31, 2023

Task Category	Date	Professional	Hours	Activity
9	1/28/2023	Bromberg, Brian	0.5	Review Avrio retention issues.
9	1/29/2023	Diaz, Matthew	0.6	Review Debtors' proposed retention bonuses.
9	1/30/2023	Diaz, Matthew	0.4	Continue to evaluate proposed retention bonuses.
<b>9 Total</b>			<b>3.0</b>	
16	1/23/2023	Bromberg, Brian	1.1	Review emergence checklist issues.
16	1/23/2023	Bromberg, Brian	0.4	Review presentation on emergence from the Debtors.
16	1/23/2023	Diaz, Matthew	1.1	Review presentation from Debtors re: emergence considerations.
16	1/24/2023	Diaz, Matthew	0.6	Review potential emergence workstreams and key tasks.
16	1/24/2023	Kurtz, Emma	1.2	Prepare analysis of split in distributable value to privates vs. publics.
16	1/25/2023	Bromberg, Brian	0.4	Response to counsel questions on updates re: emergence.
16	1/25/2023	Diaz, Matthew	1.3	Review updated distributable value recovery analysis.
16	1/26/2023	Diaz, Matthew	1.1	Continue to review updated recovery analysis.
16	1/26/2023	Kurtz, Emma	0.8	Prepare updates to distributable value analysis per comments from team.
16	1/27/2023	Bromberg, Brian	1.2	Review prior distribution analyses to evaluate potential changes.
16	1/27/2023	Bromberg, Brian	0.4	Review prior plan analyses to understand updates.
16	1/27/2023	Bromberg, Brian	0.6	Review emergence documents.
16	1/27/2023	Diaz, Matthew	2.4	Detail review of the updated recovery presentation.
16	1/29/2023	Bromberg, Brian	0.9	Review emergence issues raised by Debtors.
16	1/30/2023	Bromberg, Brian	1.5	Review updated distributions presentation.
16	1/31/2023	Bromberg, Brian	0.9	Review potential emergence workstreams re: healthcare team.
16	1/31/2023	Diaz, Matthew	0.6	Review emergence issues and workstreams.
16	1/31/2023	Shafer, Patterson	1.0	Review of potential emergence workstreams, including transfer of licenses.
<b>16 Total</b>			<b>17.5</b>	
18	1/6/2023	Bromberg, Brian	3.2	Review Sackler asset report update.
18	1/6/2023	Diaz, Matthew	1.4	Review updated Sackler net assets reporting re: B-Side.
18	1/9/2023	Bromberg, Brian	0.7	Continue to review Sackler asset reports.
18	1/9/2023	Diaz, Matthew	1.4	Review draft analysis of Sackler B-Side net assets to provide comments. Prepare draft slides re: updated B-Side net asset values and associated coverage of settlement agreement obligations.
18	1/12/2023	Kurtz, Emma	2.4	agreement obligations.
18	1/13/2023	Bromberg, Brian	0.8	Review updated analysis of B-side asset values and coverage.
18	1/13/2023	Diaz, Matthew	2.1	Review updated Sackler A-Side net assets and investment analysis.
18	1/18/2023	Bromberg, Brian	0.4	Review prior Sackler asset analysis to compare to current coverage.
18	1/18/2023	Bromberg, Brian	0.6	Review Sackler settlement agreement to understand reporting requirements.
18	1/18/2023	Bromberg, Brian	1.2	Review Sackler A-side net assets report.
18	1/18/2023	Kurtz, Emma	1.6	Prepare analysis of update A-side net assets report to evaluate changes and identify issues.
18	1/19/2023	Bromberg, Brian	0.6	Review draft presentation for AHC re: Sackler net assets.
18	1/19/2023	Bromberg, Brian	0.6	Continue to review updated Sackler net asset reports.
18	1/27/2023	Bromberg, Brian	0.9	Review Sackler settlement agreement to evaluate requirements for asset reporting.
18	1/27/2023	Bromberg, Brian	0.5	Draft follow up requests for Sackler advisors re: net assets.
18	1/28/2023	Bromberg, Brian	0.6	Review Sackler asset issues.
<b>18 Total</b>			<b>19.0</b>	
20	1/10/2023	Diaz, Matthew	0.5	Participate in call with the Debtors advisors to discuss case updates.
20	1/10/2023	Kurtz, Emma	0.4	Attend bi-weekly FA call to discuss case updates.
20	1/23/2023	Diaz, Matthew	1.3	Participate in call with the Debtors and the working group to discuss Purdue key issues.
20	1/27/2023	Diaz, Matthew	0.5	Participate in call with the Debtors' and the UCC's professionals to discuss key issues.
<b>20 Total</b>			<b>2.7</b>	
21	1/25/2023	Bromberg, Brian	1.0	Participate in call with AHC and advisors to discuss business plan and operational update.
21	1/25/2023	Diaz, Matthew	1.0	Participate in Committee meeting to discuss potential ruling, operations and insurance issues.
21	1/25/2023	Diaz, Matthew	0.3	Review presentation materials to prepare for the Committee meeting.
21	1/25/2023	Kurtz, Emma	1.0	Attend AHC update meeting to discuss business update.
<b>21 Total</b>			<b>3.3</b>	
24	1/20/2023	Diaz, Matthew	0.6	Review draft December fee application.
24	1/20/2023	Kurtz, Emma	1.8	Prepare draft December fee application per local rules.
<b>24 Total</b>			<b>2.4</b>	
28	1/23/2023	Bromberg, Brian	0.6	Review prior analysis of IAC business plan.
<b>28 Total</b>			<b>0.6</b>	
<b>Grand Total</b>			<b>95.1</b>	